Drug intelligence / Profile preview

gallium-68-DOTA-cetuximab

Development stage: Unknown
Lead developer: Timothy Marr
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Gallium-68-DOTA-cetuximab is an investigational radioimmunoconjugate consisting of cetuximab—a chimeric IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR)—conjugated to the macrocyclic chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and radiolabeled with the positron-emitting radioisotope gallium-68. It is being investigated as a diagnostic PET imaging agent in a theranostic clinical trial led by Dr. Timothy Marr at Fremantle Hospital. The agent is designed to assess tumor EGFR expression and uptake in patients with advanced head and neck squamous cell carcinoma (HNSCC) who have exhausted standard surgical and radiotherapy options. Patients demonstrating sufficient tumor uptake of gallium-68-DOTA-cetuximab may then proceed to targeted radioimmunotherapy with therapeutic counterparts such as rhenium-188-DOTA-cetuximab or lutetium-177-DOTA-cetuximab.

Other names: gallium-68-cetuximabgallium68-cetuximabgallium 68-cetuximab68Ga-DOTA-cetuximab68Ga-cetuximabgallium Ga 68-DOTA-cetuximab

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on gallium-68-DOTA-cetuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallium-68-DOTA-cetuximab.

Explore the full profile